Fierce Pharma Asia—Gilead's synthetic lethality deal; A Tokyo biotech IPO; Novo’s Ozempic China sales dip

20th February 2026 Uncategorised 0

Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-1 competition in China. And more.

More: Fierce Pharma Asia—Gilead's synthetic lethality deal; A Tokyo biotech IPO; Novo’s Ozempic China sales dip
Source: fierce